CA Patent

CA3254279A1 — Dosage forms and use thereof

Assigned to Triastek Inc · Expires 2025-03-18 · 1y expired

What this patent protects

A method for 3D printing an oral drug dosage form comprises providing a homogenous melted mixture of an API and a first erodible material, a melted substrate, and a melted second erodible material; extruding the homogenous melted mixture through a printing nozzle; depositing the …

USPTO Abstract

A method for 3D printing an oral drug dosage form comprises providing a homogenous melted mixture of an API and a first erodible material, a melted substrate, and a melted second erodible material; extruding the homogenous melted mixture through a printing nozzle; depositing the extruded mixture on a planar surface; separately extruding the melted substrate and the melted second erodible material through the printing nozzle; separately depositing the extruded melted substrate and the extruded melted second erodible material on the planar surface, thereby obtaining the oral dosage form. The dosage form comprises a water insoluble substrate forming a compartment and a drug content contained within the compartment. The drug content comprises the first erodible material admixed with the API. The compartment is sealed by a plug comprising die second erodible material not admixed with the API.

Drugs covered by this patent

Patent Metadata

Patent number
CA3254279A1
Jurisdiction
CA
Classification
Expires
2025-03-18
Drug substance claim
No
Drug product claim
No
Assignee
Triastek Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.